CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (NASDAQ:CERS) announced today that the Belgian Red Cross, Service Francophone du Sang (SFS), has signed a contract to purchase the INTERCEPT platelet system. The SFS is one of two major Red Cross blood services in Belgium, supplying blood to the Wallonia region and part of Brussels, with principal blood centers in Brabant-Hainaut, Liège, and Namur. Approximately 30% of Belgium’s platelet components, an estimated 17,500 units annually, are produced by the SFS.
